key: cord-0955981-7w2e3h65
authors: Leonel Tavares-Júnior, José Wagner; Caetano de Souza, Ana Célia; Pereira Borges, José Wicto; Oliveira, Danilo Nunes; Siqueira-Neto, José Ibiapina; Sobreira-Neto, Manoel Alves; Braga-Neto, Pedro
title: Covid-19 Associated Cognitive Impairment: A Systematic Review
date: 2022-04-18
journal: Cortex
DOI: 10.1016/j.cortex.2022.04.006
sha: 86026aca657a6775f36cf34d99d73a150c555bed
doc_id: 955981
cord_uid: 7w2e3h65

INTRODUCTION: COVID-19 has a wide range of clinical manifestations. Neurological manifestations in COVID-19 patients were demonstrated during the pandemic, including cognitive impairment. This study aimed to determine any relationship between COVID-19 and cognitive complaints, such as dementia, mild cognitive impairment (MCI), or subjective cognitive decline (SCD). METHODS: We performed a systematic review of MEDLINE via Ebsco, Cochrane EMBASE, SCOPUS, and LILACS electronic databases of observational studies with COVID-19 patients confirmed by serology or PCR who developed new cognitive impairment or deteriorated from previous cognitive impairment after infection. This review protocol was recorded on PROSPERO with registration number CRD 42021241590. RESULTS: A total of 3.520 articles were retrieved and read. Twenty-two studies were selected for our review. A wide range of cognitive assessment tools (n=25) was used. The most described affected domains in these studies were executive functions, attention, and episodic memory. Thirteen studies showed a pattern of cognitive impairment in processing speed, inattention, or executive dysfunction assessed through working memory. CONCLUSION: This review highlights the high frequency of cognitive impairment after COVID-19 infection. However, we were unable to differentiate whether the cognitive impairment found corresponded to mild cognitive impairment or dementia through data from selected studies, and this issue serves as one objective of future studies to be addressed on this topic.

evaluated in COVID-19 patients. A Chinese study evaluated the cognition of 29 COVID-19 patients using digital questionnaires, relating cognitive complaints to high C-reactive protein levels during the disease's acute phase. 5 Another study evaluated cognitive impairment in outpatients, using Mini-Mental State Evaluation (MMSE), Montreal Cognitive Assessment (MoCA), Hamilton Rating Scale for Depression, and Functional Independence Measure (FIM), finding 80% of cognitive impairment. 6 Moreover, different cognitive presentations have been described, such as encephalopathy associated with severe conditions 7 and akinetic mutism associated with frontal hypometabolism. 8

Regarding cognitive manifestations pathophysiology, a more severe neurological manifestations in patients with APOE 4 allele of Apolipoprotein E has been described. 9 This association is significant since the same allele confers a higher risk of sporadic Alzheimer's disease (AD). 10 The growing population aging over the past few decades has been associated with increased cognitive disorders. Data from Alzheimer's Disease International (ADI) report 46.8 million people living with dementia worldwide in 2015. This number is estimated to be around 74.5 million in 2030 and 131.5 million in 2050. Alzheimer's disease is the most common form of dementia and accounts for 50-70% of dementia cases. 11 The prevalence of mild cognitive impairment (MCI) is 12-18% among adults over 65 years of age, and the annual progression rates from MCI to AD are 10-15%. 12 Neuropathological

Alzheimer's disease, involving tau protein neurofibrillary tangles, beta-amyloid deposits, and neurodegeneration. Also, a minor injury burden emerges when MCI represents a stage before AD, which is theoretically susceptible to medicating action. 13 Besides these conditions, subjective cognitive decline is a condition before MCI and a possible dementia precursor. It represents individuals with cognitive complaints without objective J o u r n a l P r e -p r o o f evidence of cognitive impairment. 14 Therefore, it is crucial to identify whether COVID-19 possible neurologic lesions are associated with more significant cognitive impairment.

This study aimed to determine any relationship between COVID-19 and cognitive complaints, such as dementia, mild cognitive impairment (MCI), or subjective cognitive decline (SCD).

We performed a systematic review of observational studies based on the recommendation from the Cochrane Collaboration. 15 This review protocol was registered on PROSPERO -International Prospective Register of Systematic Reviews-under registration number CRD 42021241590.

The search strategy will be performed to enhance methodological transparency and improve the reproducibility of the findings, following the PRISMA checklist. 16 This systematic review study included six stages: 1formulating the central research question (theme identification);

Step 2defining the inclusion and exclusion criteria and literature search;

Step 3categorizing primary studies (defining data to be extracted from the selected studies);

Step 4assessing the studies included;

Step 5interpreting results; 6 performing knowledge synthesis of the results obtained from the studies assessed. [17] [18] [19] Additionally, we used the PICo method (Population; Interest; Context) acronym, 20

where "P" is the study population (patients with confirmed COVID-19); "I" is the interest evaluated (cognitive impairment); and "Co" is the context (risk of developing cognitive impairment 

For the qualitative synthesis of the systematic review, the analyzes will follow three steps: 1) preliminary synthesis of the included studies, from the identification of their characteristics, their clinical contexts, the tools used to measure cognitive decline and the cognitive results found; 2) exploration of the relationships between study data, identifying those that work with similar instruments and outcomes or even different instruments dealing with similar outcomes; 3) and evaluation of the robustness of the synthesis, which includes criticism about the methodological quality of the included studies and how this quality influences the results of the primary studies. 24

In addition, we dicotomized studies between those that included acute and subacute phase patients (<12 weeks from COVID-19 onset) from those that evaluated cognitive impairment after this phase (> 12 weeks from COVID-19 onset), in order to differentiate COVID-19 acute and subacute from chronic effects on cognition. 25

At the end of the synthesis process, the analysis of the relationships within and between the studies described led to an overall assessment of the strength of the available evidence to draw conclusions based on a narrative synthesis. 24 Display data matrices were developed in the form of tables to present the results of the systematic review.

heterogeneity was qualitatively explored in the organization of the analysis process, considering methodological similarities and differences between the included studies.

Cochrane Collaboration Risk of Bias Tool was employed to classify the included studies' risk of bias, considering the following domains: inadequate patient selection and inclusion; controlling for confounding factors; blinding of investigators and outcome evaluators; incomplete outcome data. Risk of bias was thus classified as low, high, or unknown » http://handbook-5-1.cochrane.org/.

Insert Table 1 here.

Insert Table 2 here.

J o u r n a l P r e -p r o o f Figure 1 shows the flowchart of the study selection process according to the PRISMA guidelines. A total of 3,520 articles were retrieved and read. Twenty-two studies were selected for our review. Sixteen studies included patients in COVID-19 acute and subacute phases and 6 involved only patients after 12 weeks of onset. Not all studies cited the frequency of cognitive impairment. In the studies cited in J o u r n a l P r e -p r o o f 9 Tavares-Júnior domains and described them. The affected domains most described in these studies were executive functions, attention, and episodic memory, described respectively in 9, 7, and 7 studies. All 13 studies showed a pattern of cognitive impairment in processing speed, inattention, or executive dysfunction assessed through working memory (Table 3) .

However, data from selected studies could not differentiate whether the cognitive impairment found corresponded to mild cognitive impairment or dementia. The studies

have not evaluated the loss in daily life activities.

Regarding the studies that evaluated patients in the acute/subacute phases ( The studies did not find specific alterations in structural neuroimaging exams (brain computed tomography or magnetic resonance imaging). Two of the selected studies evaluated patients in the acute phase with a cranial positron emission tomography scan, finding frontoparietal hypometabolism in patients with encephalopathy 29,32 .

All articles were submitted to bias risk assessment (figure 2). The overall risk of selection bias was high in 20 studies, while the risk for controlling for confounding factors and attrition was low in 16 and 18 studies, respectively. In turn, the risk of performance bias and detection bias was high in 10 studies each.

Insert Table 3 here. Neurologic symptoms may persist in the postacute phase and constitute a "long Regarding patient assessment methods, as would be expected, some studies used tele-assistance services during the critical phase of the pandemic in their respective countries. 5,50 They are essential alternatives and can therefore play a triage role. 58

However, it is essential to mention the lack of studies with extensive neuropsychological assessment.

This review study has some important limitations. First, some studies do not mention cognitive impairment prevalence or incidence. Furthermore, almost all studies did not have patients' previous cognitive assessments. Furthermore, no information was available about cognitive impairment subtype (MCI, AD, other neurodegenerative diseases, e.g.) in almost all studies. Another caveat is that most studies did not have control groups, precluding direct comparison. In addition, it was not possible to compare the most affected cognitive domains between studies before and after 12 weeks of Covid-19 infection. Another potential limitation of this systematic review was the wide variety of cognitive assessment instruments employed, influencing external validity. Lastly, no study included in this review used a complete cognitive neuropsychological evaluation, the gold standard assessment method. These limitations made it impossible to perform a meta-analysis.

On the other hand, a strength of this systematic review is its reproducible and transparent procedure for literature systematic review. When publishing the research, the protocol is essential to display strategy clarity and reduce bias risk. 59 In terms of future directions, it is essential to implement clinical research using control groups, using extensive neuropsychological assessment to determine the most affected cognitive domains, employing imaging and cerebrospinal fluid (CSF)

biomarkers for neurogenerative diseases such as Alzheimer's disease, in order to elucidate specific pathophysiological changes by COVID-19. Ideally, individuals with prior neurocognitive follow-up, including biomarkers and prior cognitive assessment, should be included in future studies. Likewise, the inclusion of patients with previous cognitive impairment is essential to evaluate these patients' evolution. Another important group to be assessed is the low education patients, bringing psychometric data from this population and assessing whether low education, via low cognitive reserve, adversely affects cognition after the COVID-19 condition.

This review highlights the high frequency of cognitive impairment after COVID-19 infection. However, we could not differentiate whether the cognitive impairment identified corresponded to mild cognitive impairment or dementia through data from selected studies, which is one objective of future studies to be addressed on this topic. J o u r n a l P r e -p r o o f

the Wechsler Memory Scale -IV (WMSIV), Digits forward and Backward, Letter and Numbers, Trail Making Test A and B (TMT), Symbol Digit Modalities Test (SDMT)

Phonemic and Semantic fluency and Boston Naming

computerized attentive tasks: Vigilance Task (VT)

Modified Telephone Interview for Cognitive Status (TICS-M)

Short-term memory, attention and concentration/language tasks 20-100 days from Covid-19

Verbal learning -immediate, and delayed memory subtests from the Subtest Screen for Cognitive Impairment in Psychiatry (SCIP), animal naming test (ANT) from the Controlled Oral Word Association Test (COWAT) for Amongst survivors, the prevalence of moderately impaired immediate verbal memory and learning was 38%, delayed verbal memory (11.8%), verbal fluency (34.6%) and working memory

Brief Repeatable Battery of Neuropsychological Tests (BRB-NT)

Of all patients, 42.1% had processing speed deficits

Rey Auditory Verbal Learning Test, Delayed Recall from the Benson Figure Test, Trail Making B, Wisconsin Card Sorting Test, Stroop Test, phonological fluency. Benson Figure and Clock Drawing Test, Multilingual Naming Test and semantic fluency Memory (p=0.016, Cohen's d= 0.73), attention (p<0.001, Cohen's d=1.2), executive functions

Test de Aprendizaje Verbal España-Complutense (TAVEC), Test of attentional performance (TAP)

Year Cognitive Assessment Tool used MMSE/ MoCA values FAB values

MoCA MoCA (± standard deviation)

MMSE telephone version Italian telephone Mini Mental State Examination (I-tel MMSE), median (IQR)

MoCA global score 18-25 = 14 patients (54%) mean score (SD) 20.93 (2.05), MoCA global score 10-17 = 4 patients (15%) mean score

computerized attentive tasks: Vigilance Task (VT)

Mean MoCA scores -> patients -17

MoCA Mean MoCA scores (SD) 23 (5.02)

MoCA Mean (±SD) score in the MoCA performed 6 months after the start of the SARS-CoV-2

MoCA Age 18-29 -> Mean MoCA Score in cases 25

Age 30-49 -> Mean MoCA Score in cases 25.9 ± 2.3 x Mean MoCA score in controls 25

Mean MoCA Score in cases 24 ± 3.5 x Mean MoCA score in controls 24

MoCA All patients MoCA <26 -29 patients, Mean scores (SD) MoCA 28 (26-29); Severe disease requiring ICU MoCA <26 -8 patients, Mean f scores (SD) MoCA 28 (25-28); Moderate severity, hospitalization, non-ICU MoCA <26 -20 patients

Mild severity, outpatient, MoCA <26 -1 patient, Mean scores (SD)

Rey Auditory Verbal Learning Test, Delayed Recall from the Benson Figure Test, Trail Making B, Wisconsin Card Sorting Test, Stroop Test, phonological fluency. Benson Figure and Clock Drawing Test, Multilingual Naming Test and semantic fluency Mean MoCA scores -> Controls -27

Telephone MoCA 101 cases -median MoCA 17 (13-19) 114 controls -median MoCA

SD = 3.8) than non-hospitalized ones

TMT, Stroop, verbal fluency tasks, and the 15-Objects Test Walle

Frontal Assessment Battery (FAB), Hopkins verbal learning revised (HVLT-R)

J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f FIGURE 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies (above). Risk of bias summary: review authors' judgements about each risk of bias item for each included study (below).